Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tecogen Inc. filings document the regulatory record for a Delaware operating company with common stock listed on NYSE American under TGEN. The company's Form 8-K reports furnish earnings releases, supplemental presentation materials, Regulation FD product communications, advisory agreement matters, and other events tied to its clean energy products and chiller applications.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Other disclosures address related-person transactions, promissory note matters, capital structure, risk factors referenced in periodic reports, and governance controls around company agreements and public communications.
Form 4 filing for Tecogen Inc. (TGEN) discloses that director Ahmed Ghoniem received a new equity award on 24 Jul 2025.
- Security: Non-qualified stock option granting the right to purchase 25,000 common shares.
- Exercise price: $8.35 per share.
- Vesting: 25 % annually (fully vested after four years, per footnote 1).
- Expiration: 24 Jul 2035, giving a 10-year term after the first vesting date.
- Post-grant holdings: Filing shows 237,723 derivative securities held directly (includes the new option).
- Role: Ghoniem is marked as a Director; no change in status or control is indicated.
The transaction is classified under code “A” (grant) and represents routine director compensation rather than an open-market purchase or sale. No non-derivative share activity or cash proceeds are reported, and no other executives are listed. Financial performance metrics, earnings data, or guidance are not included in this filing.
Form 4 filing synopsis: Tecogen Inc. (TGEN) director Earl R. Lewis was granted 25,000 non-qualified stock options on 07/24/2025 at an exercise price of $8.35 per share. The award vests 25 % each year and carries a 10-year term, expiring 07/24/2035. No common shares were bought or sold and no cash changed hands at the time of grant.
After this transaction, Lewis holds 91,250 derivative securities (options) in total, all recorded as direct ownership. The filing represents routine equity compensation aimed at aligning the director’s incentives with long-term shareholder value. Because the transaction involves options rather than immediate share issuance, near-term cash flow and ownership percentages are unaffected; any dilution would occur only if the options are exercised in the future.
Tecogen Inc. (TGEN) Form 4: On 07/24/2025, director Angelina Galiteva was granted a non-qualified stock option for 25,000 shares of common stock at an exercise price of $8.35. The option vests 25 % annually and expires on 07/25/2035. No shares were sold or otherwise disposed of in this filing. Following the grant, Galiteva’s total derivative holdings stand at 225,000 option-linked shares. The filing, dated 07/28/2025, shows the transaction was made in a direct ownership capacity; there is no indication of indirect ownership or group filing. No non-derivative transactions were reported.
Tecogen (TGEN) filed an 8-K announcing governance and compensation changes dated 24 Jul 2025. The board has split the CEO and CFO/Treasurer roles; CEO Dr. Abinand Rangesh resigned as CFO/Treasurer and remains CEO & director. Roger P. Deschenes, CAO since Sept 2020 and former division CFO at L3, was appointed CFO, Principal Financial Officer and Treasurer while retaining his CAO duties, a move intended to strengthen internal controls.
Compensation adjustments: the committee raised Deschenes’ salary to $180k and granted equity worth ≈$200k (17,964 restricted shares plus 12,063 ISOs, 25 % annual vesting). Rangesh received ≈$600k in equity (53,892 RSAs, 24,075 ISOs, 12,048 NQ options). General Counsel John K. Whiting IV and VP Business Development Stephen Lafaille each received ≈$200k in equity and salary increases to $180k. All options are priced at the 24 Jul 2025 NYSE American close.
The board also authorized Dr. Rangesh to grant up to $200k in options to non-executive employees. A press release confirming Deschenes’ appointment was issued 28 Jul 2025 (Exhibit 99.1). No financial performance data were disclosed.
On 21 Jul 2025, Tecogen Inc. (TGEN) filed an 8-K announcing the closing of a firm-commitment underwritten public offering of 3,985,000 common shares (incl. 485,000 overallotment) at $5.00 per share. Gross proceeds equal roughly $19.9 million; after underwriting discounts and estimated expenses, net proceeds are about $18.16 million.
Roth Capital Partners served as sole manager and underwriter. Management intends to allocate the cash to product development, expanded sales & marketing, additional staffing, capital expenditures, and working capital as the company pursues entry into the data-center market. Exhibit 99.1 contains a related press release, furnished but not deemed filed under the Exchange Act.
Stephen Lafaille, VP of Business Development at Tecogen, reported significant insider trading activity through multiple transactions between March and June 2025. The transactions reveal a pattern of option exercises and subsequent stock sales at progressively higher prices.
Key transaction highlights:
- Initial purchase of 400 shares at $2.50 on March 3, 2025
- Exercised and sold multiple tranches of options: - 10,000 shares ($0.71 exercise, sold at ~$4.88) - 15,000 shares ($0.71 exercise, sold at $5.00) - 25,000 shares ($1.10 exercise, sold at ~$5.98) - 10,000 shares ($1.10 exercise, sold at $7.25)
The insider maintains ownership of 400 shares post-transactions. Notable option holdings include remaining rights to purchase 40,000 shares at $0.71 (expires 2030) and 45,000 shares at $1.10 (expires 2032), subject to vesting conditions tied to EBITDA performance metrics.